CureVac (CVAC) has released an update.
CureVac, a biopharmaceutical company, has reached a new licensing deal with GSK for up to €1.45 billion, signaling strong confidence in its mRNA technology platform. The company is also streamlining operations with a 30% workforce reduction to prioritize its focus on oncology and infectious diseases, while extending its cash runway into 2028. Furthermore, CureVac is advancing its glioblastoma vaccine candidate, CVGBM, into further clinical studies.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
